EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Entinostat-Bortezomib Hybrids against Multiple Myeloma

Angelica Ferro, Dafni Graikioti iD, Emre Gezer iD, Constantinos M Athanassopoulos iD, Muriel Cuendet iD

Molecules · 02.02.2023 · 28 (3) · 1456

DOI: 10.3390/molecules28031456 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, online erschienen am 02.02.2023. Verfasst von Angelica Ferro und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, University of Geneva, 1211 Geneva, Switzerland. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although proteasome inhibitors have emerged as the therapeutic backbone of multiple myeloma treatment, patients often relapse and become drug refractory. The combination between proteasome and histone deacetylase inhibitors has shown to be more efficient compared to monotherapy by enhancing the anti-myeloma activity and improving the patient’s lifetime expectancy. Hybrid molecules, combining two drugs/pharmacophores in a single molecular entity, offer improved effectiveness by modulating more than one target and circumventing differences in the pharmacokinetic and pharmacodynamic profiles, which are the main disadvantages of combination therapy. Therefore, eleven histone deacetylase-proteasome inhibitor hybrids were synthesized, combining pharmacophores of entinostat and bortezomib. Compound 3 displayed the strongest antiproliferative activity with an IC50 value of 9.5 nM in the multiple myeloma cells RPMI 8226, 157.7 nM in the same cell line resistant to bortezomib, and 13.1 nM in a 3D spheroid model containing multiple myeloma and mesenchymal stem cells. Moreover, the compound inhibited 33% of histone deacetylase activity when RPMI 8226 cells were treated for 8 h at 10 µM. It also inhibited the proteasome activity with an IC50 value of 23.6 nM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntineoplastic AgentsHumansBortezomibProteasome Endopeptidase ComplexBoronic AcidsCell Line, TumorNeoplasm Recurrence, LocalProteasome InhibitorsHistone Deacetylase InhibitorsHistone DeacetylasesDrug Resistance, NeoplasmBenzamidesPyridines

Stichwörter der Autor:innen

HDAC inhibitorsdrug resistancehybrid inhibitorsmultiple myelomaproteasome inhibitors

Substanzen

BortezomibAntineoplastic AgentsProteasome Endopeptidase ComplexBoronic AcidsProteasome InhibitorsHistone Deacetylase InhibitorsHistone DeacetylasesentinostatBenzamidesPyridines

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, University of Geneva, 1211 Geneva, Switzerland.
  • Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1211 Geneva, Switzerland.
  • Synthetic Organic Chemistry Laboratory, Department of Chemistry, University of Patras, 26504 Patras, Greece.

ORCID-Profile: Dafni Graikioti, Emre Gezer, Constantinos M Athanassopoulos, Muriel Cuendet

Zitieren

APA

Ferro, A., Graikioti, D., Gezer, E., Athanassopoulos, C. M., & Cuendet, M. (2023). Entinostat-Bortezomib Hybrids against Multiple Myeloma. Molecules, 28(3), 1456. https://doi.org/10.3390/molecules28031456

Vancouver

Ferro A, Graikioti D, Gezer E, Athanassopoulos CM, Cuendet M. Entinostat-Bortezomib Hybrids against Multiple Myeloma. Molecules. 2023;28(3):1456. doi:10.3390/molecules28031456

BibTeX
@article{Ferro2023,
  author = {Ferro, Angelica and Graikioti, Dafni and Gezer, Emre and Athanassopoulos, Constantinos M and Cuendet, Muriel},
  title = {Entinostat-Bortezomib Hybrids against Multiple Myeloma},
  journal = {Molecules},
  year = {2023},
  volume = {28},
  number = {3},
  pages = {1456},
  doi = {10.3390/molecules28031456}
}
Kostenlos starten →